Founded in 2020, Immunocan is dedicated to building next‑generation antibody discovery platforms powered by gene‑editing technologies. The company's proprietary MASIRT® (Massive-fragment Across Species In situ Replacement Technology) has achieved three core breakthroughs: leveraging a linear artificial chromosome strategy that significantly increases gene fragment loading capacity; enabling Mb-scale DNA in situ replacement in a single operation, significantly reducing the number of editing cycles;

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE: 300760), China's largest medical device company and #23 globally by revenue, has filed a draft prospectus for an H-share listing on the Hong Kong Stock Exchange. The move comes amid a strategic pivot toward international markets, which now account for 53% of FY2025 revenue, offsetting a 23% domestic revenue decline. Despite a 9.4% year-over-year drop in total revenue to RMB 33.28 billion and a 28% fall in net profit to RMB 8.45 billion, Mindray maintained robust R&D investment at 10.8% of revenue and generated RMB 10.14 billion in operating cash flow. The IPO aims to bolster its global brand, support M&A initiatives, and align capital structure with its increasingly international business footprint.

HJ Science Co., Ltd., a Chengdu-based clinical-stage biotech founded in 2017, has filed for a Hong Kong listing with a pre-money valuation of RMB 2.70 billion. The company focuses on small-molecule drug development across autoimmune, metabolic, and oncology indications, leveraging proprietary platforms including TSD-IAS and a Molecular Glue Technology Payload Platform. Its pipeline features nine programs, including three clinical-stage assets: HJ787 (topical TYK2 inhibitor for atopic dermatitis), HJ178 (oral GLP-1/GIP dual agonist for diabetes and obesity), and HJ891 (oral KRAS G12C inhibitor for NSCLC), with HJ197 in Phase III for hepatocellular carcinoma partnered with Junshi Biosciences. Revenue rose to RMB 13.0 million in 2025 from partnership milestones, while net loss narrowed to RMB 135.1 million. The company holds RMB 331.3 million in total liquidity as of March 2026 and plans to use IPO proceeds to fund late-stage trials and commercialization efforts.

Preliminary statistics from VCBeat tracked 11 financing events in China's healthcare sector between May 6 and 9, 2026 (excluding IPOs and private placements). The period was led by CureGene's RMB 300 million Series C round, followed by Nanochap's RMB 300 million strategic financing round.

Kexing Biopharm's origins predate the wave of innovative drugs in China by more than two decades. Over the course of its development, three key strategic decisions have shaped its current industry position and development direction.

On May 11, 2025, Sino Biopharm announced that its subsidiary CHIATAI TIANQING has entered an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the commercialization of bepirovirsen, a first-in-class antisense oligonucleotide (ASO) therapy with triple mechanism of action, in mainland China. CHIATAI TIANQING will manage import, distribution, hospital access, and all promotional activities, recognizing 100% of sales revenue, while GSK remains the Marketing Authorization Holder responsible for regulatory, quality, and global medical strategy. The initial term is 5.5 years, extendable by mutual agreement. Bepirovirsen, submitted for Chinese marketing approval in March 2026 and granted priority review, demonstrated significant functional cure rates in Phase III B-Well trials and could become the first finite-duration therapy to achieve functional cure for chronic hepatitis B—a disease affecting 75 million people in China and causing over 450,000 annual deaths.

Why do the bronchoscopy robots, developed by two industry giants with top engineering teams and years of effort, have a biopsy rate stuck at around 75%? This made Zhang Jian, an engineer, very curious. He spent months "peeling the onion" and finally clarified the essence of the problem: the first-generation bronchoscopy robot emphasizes "navigation" but lacks "real-time positioning."

Against this significant favorable policy backdrop, CuraWay Medical's percutaneous interventional surgical robot, with its clear clinical value (improved puncture accuracy, reduced complications, and lower radiation exposure), forms a synergistic advantage with the company's supporting interventional devices. This financing round will significantly accelerate the company's commercialization process, allowing it to seize the first-mover advantage in the market.

The company's core product, Evategrel (CG-0255), is a global first-in-class, next-generation P2Y12 receptor inhibitor available in both intravenous and oral formulations. Utilizing an innovative thiol-hydrolyzing prodrug design, it achieves rapid onset (less than 15 minutes for injection, less than 30 minutes for oral administration) and completely overcomes the "clopidogrel resistance" issue present in approximately 58% of the Chinese population.

Sports performance has never been solely about physical fitness. Research shows that the physical gaps among top athletes are often minimal; what truly makes the difference is the state of the brain. Distracted focus, pre-competition anxiety, and accumulated training fatigue — these "invisible" cognitive variables often determine the outcome more than muscle strength at critical moments.